Applying the evidence: Do patients with stroke, coronary artery disease, or both achieve similar treatment goals?

Stroke

Volumn 40, Issue 4, 2009, Pages 1417-1424

  Saposnik, Gustavo ^a,b,c   Goodman, Shaun G ^a   Leiter, Lawrence A ^a   Yan, Raymond T ^a   Fitchett, David H ^a   Bayer, Neville H ^c   Casanova, Amparo ^b   Langer, Anatoly ^a   Yan, Andrew T ^a  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c Stroke Research Unit   (Canada)

Author keywords

Cardiovascular disease; Diabetes; Dyslipidemia; Guidelines; Prevention; Stroke; Treatment

Indexed keywords

ACETYLSALICYLIC ACID; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ANTITHROMBOCYTIC AGENT; ATORVASTATIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTILIPEMIC AGENT; FIBRINOLYTIC AGENT; LIPID;

ADULT; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIASTOLIC BLOOD PRESSURE; DIET RESTRICTION; DOSE RESPONSE; EVIDENCE BASED MEDICINE; FEMALE; HEALTH PROGRAM; HUMAN; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; BLOOD; BLOOD PRESSURE; CANADA; CLINICAL TRIAL; MIDDLE AGED; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; OUTPATIENT; PROSPECTIVE STUDY; REGISTER; RISK FACTOR; SEX RATIO; STATISTICS; STROKE;

AGED; ANTIHYPERTENSIVE AGENTS; ANTILIPEMIC AGENTS; BLOOD PRESSURE; CANADA; CORONARY ARTERY DISEASE; EVIDENCE-BASED MEDICINE; FEMALE; FIBRINOLYTIC AGENTS; GUIDELINE ADHERENCE; HUMANS; LIPIDS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; OUTPATIENTS; PROSPECTIVE STUDIES; REGISTRIES; RISK FACTORS; SEX DISTRIBUTION; STROKE; TREATMENT OUTCOME;

EID: 65249114146     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.108.533018     Document Type: Article

References (36)

1. Goldstein LB, Adams R, Alberts MJ, Appel LJ, Brass LM, Bushnell CD, Culebras A, DeGraba TJ, Gorelick PB, Guyton IR, Hart RG, Howard G, Kelly-Hayes M, Nixon JV, Sacco RL. Primary prevention of ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council: co-sponsored by the Atherosclerotic Peripheral Vascular Disease interdisciplinary working group; Cardiovascular Nursing Council; Clinical Cardiology Council; Nutrition, Physical Activity, and Metabolism Council; and the Quality of Care and Outcomes Research interdisciplinary working group. Circulation. 2006; 113:e873-e923.
2. Saposnik G, Cote R, Phillips S, Gubitz G, Bayer N, Minuk J, Black S; Stroke Outcome Research Canada (SORCan) Working Group. Stroke outcome in those over 80: a multicenter cohort study across Canada. Stroke. 2008;39:2310-2317.
3. Sacco RL, Adams R, Albers G, Alberts MJ, Benavente O, Furie K, Goldstein LB, Gorelick P, Halperin J, Harbaugh R, Johnston SC, Katzan I, Kelly-Hayes M, Kenton EJ, Marks M, Schwamm LH, Tomsick T. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation. 2006;113:e409-e449.
4. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, Mullany CJ, Ornato IP, Pearle DL, Sloan MA, Smith SC Ir. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). J Am Coll Cardiol. 2004;44:671-719.
5. Amarenco P, Lavallee P, Touboul PI. Stroke prevention, blood cholesterol, and statins. Lancet Neurol. 2004;3:271-278.
6. Gorelick PB, Sacco RL, Smith DB, Alberts M, Mustone-Alexander L, Rader D, Ross JL, Raps E, Ozer MN, Brass LM, Malone ME, Goldberg S, Booss J, Hanley DF, Toole IF, Greengold NL, Rhew DC. Prevention of a first stroke: a review of guidelines and a multidisciplinary consensus statement from the National Stroke Association. JAMA. 1999;281: 1112-1120.
7. McAlister FA, Zarnke KB, Campbell NR, Feldman RD, Levine M, Mahon I, Grover SA, Lewanczuk R, Leenen F, Tobe S, Lebel M, Stone I, Schiffrin EL, Rabkin SW, Ogilvie RI, Larochelle P, Jones C, Honos G, Fodor G, Burgess E, Hamet P, Herman R, Irvine I, Culleton B, Wright IM. The 2001 Canadian recommendations for the management of hypertension: part two-therapy. Can J Cardiol. 2002;18:625-641.
8. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
9. Fodor IG, Frohlich JJ, Genest JJ Ir, McPherson PR. Recommendations for the management and treatment of dyslipidemia: report of the working group on hypercholesterolemia and other dyslipidemias. Can Med Assoc J. 2000;162:1441-1447.
10. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomer K, Perk I, Pyorala K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice. Eur Heart J. 2003;24:1601-1610.
11. Yan AT, Yan RT, Tan M, Hackam DG, Leblanc KL, Kertland H, Tsang JL, Jaffer S, Kates ML, Leiter LA, Fitchett DH, Langer A, Goodman SG. Contemporary management of dyslipidemia in high-risk patients: targets still not met. Am J Med. 2006;119:676-683.
12. Hackam DG, Tan MK, Honos GN, Leiter LA, Langer A, Goodman SG. How does the prognosis of diabetes compare with that of established vascular disease? insights from the Canadian vascular protection (VP) registry. Am Heart J. 2004;148:1028-1033.
13. Williams RR, Hunt SC, Schumacher MC, Hegele RA, Leppert MF, Ludwig EH, Hopkins PN. Diagnosing heterozygous familial hypercho-lesterolemia using new practical criteria validated by molecular genetics. Am J Cardiol. 1993;72:171-176.
14. Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (1-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000; 160: 459-467.
15. Deleted in proof.
16. Davidson MH, Maki KC, Pearson TA, Pasternak RC, Deedwania PC, McKenney JM, Fonarow GC, Maron DJ, Ansell BJ, Clark LT, Ballantyne CM. Results of the National Cholesterol Education (NCEP) program evaluation project utilizing novel e-technology (Neptune) II survey and implications for treatment under the recent NCEP writing group recommendations. Am J Cardiol. 2005;96:556-563.
17. Mosca L, Merz NB, Blumenthal RS, Cziraky MJ, Fabunmi RP, Sarawate C, Watson KE, Willey VJ, Stanek EJ. Opportunity for intervention to achieve American Heart Association guidelines for optimal lipid levels in high-risk women in a managed care setting. Circulation. 2005;111: 488-493.
18. Rothwell PM, Giles MF, Chandratheva A, Marquardt L, Geraghty O, Redgrave JN, Lovelock CE, Binney LE, Bull LM, Cuthbertson FC, Welch SJ, Bosch S, Alexander FC, Silver LE, Gutnikov SA, Mehta Z. Effect of urgent treatment of transient ischaemic attack and minor stroke on early recurrent stroke (EXPRESS study): a prospective population-based sequential comparison. Lancet. 2007;370:1432-1442.
19. Bhatt DL, Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: rationale and design of the clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance (CHARISMA) trial. Am Heart J. 2004;148:263-268.
20. Amarenco P, Bogousslavsky J, Callahan A III, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355:549-559.
21. Diener HC, Cunha L, Forbes C, Sivenius J, Smets P, Lowenthal A. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci. 1996;143:1-13.
22. Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, Leys D, Matias-Guiu J, Rupprecht HJ. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet. 2004;364:331-337.
23. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet. 2001;358:1033-1041.
24. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation study investigators. N Engl J Med. 2000;342:145-153.
25. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, Kirby A, Sourjina T, Peto R, Collins R, Simes R. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366: 1267-1278.
26. Hackam DG, Spence JD. Combining multiple approaches for the secondary prevention of vascular events after stroke: a quantitative modeling study. Stroke. 2007;38:1881-1885.
27. van Wijk I, Kappelle LJ, van Gijn J, Koudstaal PJ, Franke CL, Vermeulen M, Gorter JW, Algra A. Long-term survival and vascular event risk after transient ischaemic attack or minor ischaemic stroke: a cohort study. Lancet. 2005;365:2098-2104.
28. Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE I and II in nine countries. Euroaspire I and II group. European action on secondary prevention by intervention to reduce events. Lancet. 2001;357:995-1001.
29. Ovbiagele B, Saver JL, Bang H, Chambless LE, Nassief A, Minuk J, Toole JF, Crouse JR. Statin treatment and adherence to national cholesterol guidelines after ischemic stroke. Neurology. 2006;66:1164-1170.
30. Hayes SM, Dupuis M, Murray S. Issues and challenges in the assessment, diagnosis and treatment of cardiovascular risk factors: assessing the needs of cardiologists. BMC Med Educ. 2008;8:30.
31. Ovbiagele B, Saver JL, Fredieu A, Suzuki S, Selco S, Rajajee V, McNair N, Razinia T, Kidwell CS. In-hospital initiation of secondary stroke prevention therapies yields high rates of adherence at follow-up. Stroke. 2004;35:2879-2883.
32. Brown DJ. New guidelines for low-density lipoprotein levels from the National Cholesterol Education Program (NCEP): a 2004 update. Prog Cardiovasc Nurs. 2004; 19:165.
33. McPherson R, Frohlich J, Fodor G, Genest J, Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement - recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol. 2006;22:913-927.
34. MRC/BHF Heart Protection Study of cholesterol lowering with simva-statin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360:7-22.
35. LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005;352:1425-1435.
36. Lindsay MP, Kapral MK, Gladstone D, Holloway R, Tu JV, Laupacis A, Grimshaw JM. The Canadian stroke quality of care study: establishing indicators for optimal acute stroke care. Can Med Assoc J. 2005;172:363-365.